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Dengue virus (DENV) is a mosquito-borne flavivirus and a major international public health
concern in many tropical and sub-tropical areas worldwide. DENV is divided into four major
serotypes, and infection with one serotype leads to immunity against the same, but not
the other serotypes. The specific diagnosis of DENV-infections via antibody-detection is
problematic due to the high degree of cross-reactivity displayed by antibodies against
related flaviviruses, such as West Nile virus (WNV), Yellow Fever virus (YFV) or Tick-borne
encephalitis virus (TBEV). Especially in areas where several flaviviruses co-circulate or in
the context of vaccination e.g. against YFV or TBEV, this severely complicates diagnosis
and surveillance. Most flavivirus cross-reactive antibodies are produced against the highly
conserved fusion loop (FL) domain in the viral envelope (E) protein. We generated insect-
cell derived recombinant E-proteins of the four DENV-serotypes which contain point muta-
tions in the FL domain. By using specific mixtures of these mutant antigens, cross-reactivity
against heterologous flaviviruses was strongly reduced, enabling sensitive and specific
diagnosis of the DENV-infected serum samples in IgG and IgM-measurements. These
results have indications for the development of serological DENV-tests with improved
specificity.
Author Summary
The serological diagnosis of dengue is severely complicated by cross-reactivity between
antibodies against different flaviviruses. Currently available tests cannot rule out false posi-
tive results due to infections or vaccinations with related pathogens such as West Nile
virus or Yellow Fever virus. Most cross-reactive antibodies target the conserved fusion
loop (FL) domain in the E protein (the major component of the viral envelope). Therefore,
we generated insect-cell derived E proteins of DENV from the four different serotypes
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with mutations in the FL and set up an ELISA-based platform. Using these antigens we
were able to detect DENV-infections with high sensitivity. In addition, cross-reactivity
with a variety of heterologous flavivirus-infections was eliminated. The results have strong
indications for the development of simple and sensitive serological DENV-tests with
greatly improved specificity.
Introduction
Dengue virus (DENV) is a mosquito-transmitted pathogen of the family Flaviviridae, a group
of small, enveloped and positive stranded RNA-viruses. Besides DENV there are several other
human pathogenic vector-borne flaviviruses, such as yellow fever virus (YFV), West Nile virus
(WNV), tick-borne encephalitis virus (TBEV) or Japanese encephalitis virus (JEV) [1]. DENV
is endemic to over a hundred tropical and subtropical countries worldwide, and the numbers
of annual infections are strongly increasing with a current estimate of 400 million [2]. High
fever is the most common clinical symptom of a DENV-infection, but also severe complica-
tions are observed, such as dengue shock syndrome (DHS) or dengue haemorrhagic fever
(DHF). Approx. half a million hospitalizations and several thousands of fatalities are caused by
DENV every year [3,4]. Dengue viruses include four major distinct serotypes, named DENV-1
to DENV-4, and survival of an infection with one of these serotypes leads to a lifelong immu-
nity to this serotype, but not to the others [5]. In parallel to the increasing distribution of its
vector, mosquitos from the genus Aedes, DENV is emerging or re-emerging in several areas
including Europe and North America. In Europe local transmission of the virus has been dem-
onstrated in France and Croatia in 2010 [6,7]. In addition, a DENV-outbreak occurred in
Madeira in 2012 and resulted in over 2000 cases and transportation of the virus into several
other European countries [8].During the acute phase of infection, Dengue can be diagnosed by
directly detecting viral RNA or the non-structural protein 1 (NS1), which is secreted by
infected cells. About five days after onset of symptoms, these direct infection markers start to
decrease in blood and DENV-IgM antibodies appear, followed by IgG a couple of days later.
Therefore, except during the acute phase, DENV-infections are usually diagnosed by antibody-
measurements, and several serological test systems are available [reviewed in 9,10]. Whereas
IgM-detection can indicate recent primary infections, IgG-measurements are useful for detec-
tion of secondary infections, where IgM responses usually remain lower, and for serological
surveillance activities. Acute dengue infections can be confirmed via a rise in IgM or IgG levels
in paired samples [10]. One of the major problems in antibody-based diagnosis of dengue is
the similarity of structural proteins of different flaviviruses which leads to cross-reactive anti-
bodies and false positive test results [11–13]. Especially in areas where several flaviviruses co-
circulate or in the context of vaccination against e.g. YFV or TBEV, this is of concern [1,14]. As
the currently available tests cannot exclude flavivirus cross-reactivity, positive test results have
to be confirmed by virus neutralization tests, which are time consuming and require BSL-3 lab-
oratories. The E (envelope) protein is a major target of the human antibody response during
DENV infections and is used in most available tests [15]. Cross-reactive antibodies target
mainly the highly conserved fusion loop (FL) domain of the E protein which is involved in
fusion of the viral and cellular membranes [16–19]. As a consequence, the insertion of muta-
tions into the FL leads to a decrease in binding of cross-reactive antibodies, which has been
employed to develop diagnostic methods on the basis of WNV- or JEV- virus-like particles
(VLPs) [20–22]. Alternatively, other recombinant antigens than the E protein, such as NS1,
have been used to differentiate flavivirus antibodies via titer-determinations [23].
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It was shown previously that a bacterially expressed E protein fromWNV bearing four
point mutations in the FL and an adjacent loop domain can be used to serologically distinguish
WNV- from TBEV and DENV-infections [22,24] by reducing the binding of antibodies from
heterologous flavivirus infections. Here, we expand this technology to DENV. Quadruple
mutant forms of the E proteins from the different DENV-serotypes, containing the same muta-
tions as the WNV-protein [24], were generated in insect cells and analyzed as a diagnostic tool.




Drosophila S2 cells (Invitrogen) were propagated at 28°C in T-75 cm2 flasks in Schneider´s
medium supplemented with 10% FCS and 1% Pen/Strep (complete Schneider´s Medium).
Expression and purification of DENV envelope proteins
The sequences of the DENV-2 E wild type ectodomain (E-protein amino acid residues 1–399;
strain 16681) and the quadruple mutants (Equad: T76R, Q77E, W101R; L107R) of DENV sero-
types 1–4 (DENV-1: Nauru/West Pac/1974, E-protein amino acid residues 1–399; DENV-3:
Sri Lanka/1266/2000, E-protein amino acid residues 1–397; DENV-4: Dominica/814669/1981,
E-protein amino acid residues 1–399;) were synthesized (Centic Biotec) and cloned with BglII
and EcoRI into the pMT/BiP/V5-His vector (Invitrogen). Plasmids were transfected with a Ca-
Phosphate transfection kit (Invitrogen) according to manufacturer´s instructions into Dro-
sophila S2 cells. To generate stable cell lines 1 μg of pCoHygro (Invitrogen), containing a
hygromycin resistance gene, was co-transfected with each expression vector. Stably transfected
polyclonal S2 cell populations were generated after 3 weeks of selection with hygromycin B
(300 μg/ml) in complete Schneider´s Medium. These cells were then propagated at 28°C in tis-
sue culture flasks with complete Schneider´s medium containing 300 μg/ml hygromycin B and
adapted to Sf900II medium containing 600 μg/ml hygromycin B. For an expression culture,
cells were seeded at a cell density of 2–3 x106 cells/ml in 600 ml Sf900II medium in 2 l baffled
Erlenmeyer shaker flasks at 28°C and 90 rpm and were induced with 700 μMCuSo4 at a cell
density of 6 x 106 cells/ml. After 7 days the suspension culture was centrifuged for 15 min and
4000 g at 4°C and culture supernatant was concentrated and diafiltrated against His-binding
buffer (20 mM sodium phosphate, 500 mM NaCl, 10 mM Imidazole, pH7,4) using Vivaflow
50R TFF cassettes (Sartorius) according to manufacturers´ instructions. The DENV E proteins
were purified by immobilized metal affinity chromatography (IMAC) with 5 ml HisTrap FF
crude columns (GeHealthcare) and size exclusion chromatography with a 16/600 HiLoad
Superdex 200 pg column (GeHealthcare) using the ÄKTA pure 25 l chromatography system
(GeHealthcare). Purified proteins were quantified using a BCA protein assay (Pierce). Confor-
mation of the E-proteins and loss of the FL-domain structure in the Equad mutants were veri-
fied by binding studies of monoclonal antibodies recognizing DENV-2 epitopes in the domains
DI-DII (antibody DV2-44), DIII (DV2-76, DV2-96, DV2-106) and FL (DV2-29) and WNV-
specific FL-antibodies (E18 and E60) [25,26] (S1 Table).
Serum samples
22 DENV-positive serum samples were obtained from Padova University Hospital (Italy). The
confirmed DENV cases were international travelers returning from endemic countries with
diagnosis of recent infection. 15 DENV-positive serum samples and one negative control were
Mutant Envelope-Proteins for Dengue Diagnosis
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obtained from Seracare Life Sciences (USA), and 8 DENV-infected serum samples and two
negative controls were obtained from ZeptoMetrix Corporation (USA). Three DENV-infected
and one WNV-infected samples were from the Robert Koch Institute (Berlin) as part of an
external quality assessment study [12]. Serum samples positive for DENV antibodies all ful-
filled one of the following criteria: (a) positive in DENV-specific RT-PCR, (b) positive for both
DENV IgM and IgG, (c) positive in a DENV-specific virus neutralization test (VNT). Serum
samples from confirmed WNV-infections as well as sera from TBEV-infected individuals and
negative controls were derived from Italy (University of Padova). The WNV-positive samples
(IgG and IgM) were from seroprevalence studies, blood donors or patients with WNV- neu-
roinvasive disease. WNV-infections were confirmed by VNT. TBEV IgG-positive serum sam-
ples were selected from a seroprevalence study in forest rangers with a history of confirmed
TBEV infection and no previous exposure to DENV. Serum samples from YFV-vaccinated
individuals (IgG positive) participating in a randomized controlled vaccination study were
obtained from the Robert Koch Institute (Berlin, Germany). These were confirmed by VNT.
Ethics statement
Ethical approval for all serum samples from Padova University was obtained from the Padova
University Hospital ethics committee. The randomized controlled vaccination study for YFV
from the Robert Koch Institute was approved by the Charité medical ethics committee. All per-
sons participating in this research provided informed consent and all samples were analyzed
anonymously.
Antibody measurements
Indicated protein amounts of DENV-2 Ewt and Equad or DENV1-4 Equad mixtures were
coated overnight on Nunc polysorb plates (Thermo Scientific) in 100 μl coating buffer (15 mM
Na2CO3,35 mMNaHCO3 pH 9.6) at 4°C. The plates were washed three times with 350 μl per
well of PBS-0,05% Tween and blocked with 200 μl of 5% non-fat milk powder (blocking solu-
tion) for 2 h at room temperature. After a second washing step, human sera were diluted 1:100
in 100 μl blocking solution per well and incubated for 1.5 h at room temperature. Following a
third washing step, the HRP-conjugated secondary goat anti human IgG (Fisher Scientific,
1:10000 in 100 μl blocking solution per well) or rabbit anti human μ-chain IgM (Dianova,
1:7500 in 100 μl blocking solution per well) antibody was added for 1 h at room temperature.
After a fourth washing step, 100 μl TMB substrate (Biozol) per well were incubated for 30 min
at room temperature. The reaction was stopped with 50 μl 1 M H2SO4 and signals were read
out at 450 nm with background reduction at 520 nm in a micro plate reader (Infinite M200,
Tecan). All tests were performed in duplicates and in two independent experiments. The Pan-
bio Dengue IgG Indirect ELISA and was used according to the manufacturer´s instructions.
Statistical analysis
All antibody measurements were performed in duplicates in at least two independent experi-
ments. Graphical and statistical analysis of the data in boxplots was carried out using
SigmaPlot.
Results
To enhance specificity of serological DENV diagnosis we inserted 4 amino acid point muta-
tions into the conserved fusion loop (FL) domain and an adjacent loop domain of DENV wild-
type (wt) E proteins, yielding quadruple mutants for DENV serotypes 1 to 4 (DENV 1–4
Mutant Envelope-Proteins for Dengue Diagnosis
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Equad-proteins, Fig 1). The mutant proteins as well as the DENV-2 wt E-protein were overex-
pressed in Drosophila S2 cells and secreted into the culture´s supernatant. After purification by
immobilized metal affinity chromatography several unspecific proteins were co-purified.
Therefore a second purification step using size exclusion chromatography was performed to
eliminate the visible unspecific bands (Fig 2A).
To determine the optimal antigen concentration per well for an IgG-ELISA increasing
amounts of the proteins DENV-2 Ewt and DENV 1–4 Equad were incubated with three sera of
DENV- and WNV- infected or flavivirus-uninfected individuals, respectively (Fig 3). Signal
saturation of DENV-positive sera was observed with an antigen amount of approx. 200 ng per
well for DENV -1, 3 and -4 Equad and 300 ng per well for DENV-2 Ewt and Equad proteins.
Fig 1. Alignment of the amino acid sequences containing the fusion loop domain from E proteins of DENV 1–4, WNV, JEV, YFV, TBEV and the four
point mutations of the QUAD proteins. Amino acids numbering: 1 is start of the E protein.
doi:10.1371/journal.pntd.0004218.g001
Fig 2. A: Expression and purification of DENV-2 Ewt and Equad from Drosophila S2 culture supernatants; supernatant before induction (b.ind.),
after 7 days of expression culture (7 d expr.), concentrated via tangential flow (Conc.) and the two step purification with immobilized imidazole
affinity (IMAC) and size exclusion chromatography (SEC) were separated on a 10% SDS-PAGE gel under reducing conditions. B: 6 μg of purified
DENV1-4 (D1-D4) Equad and DENV-2 Ewt proteins were analyzed with SDS-PAGE. Proteins were stained with Coomassie blue. Size of molecular
weight markers in kilo Daltons is indicated on the left.
doi:10.1371/journal.pntd.0004218.g002
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Two of the three DENV-positive sera showed a substantial decrease in binding to the DENV-1
and DENV-2 mutant proteins (Fig 3A and 3B) as compared to the DENV-2 wild type version,
but the values were still detectable when 50 ng or more was used. TwoWNV-positive samples
bound to the wild type antigen as strongly as the DENV-positive sera, and the third started to
show such cross-reactivity with more than 200 ng of antigen per well (Fig 3E). However, all
WNV sera lost binding almost completely when the mutant antigens were used except for
DENV-4 Equad, where two WNV-positive sera still showed substantial signals for 200 ng of
antigen per well or more (Fig 3D). Negative sera showed negligible signal intensities for all pro-
teins in all amounts tested. Based on these results an antigen amount of 300 ng per well was
chosen for the analysis of a larger serum panel with DENV-2 wt and DENV-2 Equad in an IgG
ELISA.
First, sera from 38 DENV-, 13 WNV-, 19 TBEV- infected, 8 YFV vaccinated and 7 unin-
fected individuals were incubated with DENV-2 Ewt protein (Fig 4A). Strong binding for
DENV-positive samples was observed (mean absorbance value 2.36), however, several WNV-
and TBEV- positive sera (mean values 1.26 and 0.82, respectively) showed cross-reactive
Fig 3. Antigen titration using the indicated amounts of DENV-1 (A), -2 (B), -3 (C) and -4 (D) Equad and DENV-2 Ewt (E) proteins with three different
DENV, WNV and negative (NEG) human sera.Measurements were performed in duplicates in at least two independent experiments.
doi:10.1371/journal.pntd.0004218.g003
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signals which were in the range of DENV-infected sera. Samples from YFV-vaccinated individ-
uals showed a reduced cross-reactivity in comparison to WNV- and TBEV-infected serum
samples. When using the DENV-2 Equad protein, the cross-reactivities of WNV- and TBEV-
infected samples were significantly reduced (mean values 0.106 and 0.160, respectively) (Fig
4B). In addition, the signal intensities of the DENV-positive samples changed. The mean value
was reduced to 1.9 and the overall signal range increased from 2.1 to 2.4 in comparison to
DENV-2 Ewt. Next, a mixture of the Equad proteins of all four serotypes was prepared (DENV
1–4 Equad Mix). Based on the titration curves (Fig 3) a total amount of 160 ng was found to be
optimal in specificity and sensitivity, consisting of 50 ng of DENV 1–3 Equad respectively and
10 ng of DENV-4 Equad. The proportional amount of DENV-4 Equad was reduced compared
to the other serotypes because it elicited a higher cross-reactivity with heterologous flaviviral
sera (Fig 3D). The mixture was tested with the same serum panel. This resulted in an increase
of the 25th percentile from 1.36 to 1.6, demonstrating a higher sensitivity compared to using
only DENV-2 Equad. At the same time, cross-reactivity of WNV- and TBEV-positive sera was
even further reduced (mean values 0.063 and 0.084, respectively) showing a higher specificity
of the test in comparison to using DENV-2 Equad only. The stasticial analysis of the data is
shown in S2 Table. The five DENV-positive sera detected as outliers on the lower end of the
DENV-panel using the mutant antigens in Fig 4 were numbered. Whereas sera 1, 2 (both
unknown DENV serotype infections) and 3 (DENV-3 infection) showed decreased binding to
the DENV-2 Equad-protein as compared to the wild type, their signals increased when using
the DENV 1–4 Equad mix. Also the signals of samples 4 and 5 (DENV-1 and -2 infections,
respectively) decreased with the DENV-2 Equad compared to the wild type but were even
lower with the mutant mixture (Fig 4C).
To compare these results with a state-of-the-art diagnostic method, a number of the serum
samples were analyzed with a commercially available DENV-IgG ELISA. The test detected 3/3
DENV-positive sera as positive and 3/3 negative sera as negative. However, 10/10 WNV-
infected sera were detected as positive with several OD-values similar to DENV-infected sera.
Fig 4. 300 ng per well of DENV-2 Ewt (A) and Equad (B) and 160 ng per well of a DENV 1–4 Equadmixture (C) were tested with DENV-WNV- and
TBEV- infected and YFV-vaccinated sera compared to negative (NEG) samples in an IgG-ELISA (n = number of individuals). Bottom and top of the
boxes are the first and third quartiles. The median signal is depicted as a line inside the box. Whiskers represent the 9th and the 91st percentile. Outliers in B
and C are marked with numbers (1–5). Measurements were performed in duplicates in at least two independent experiments.
doi:10.1371/journal.pntd.0004218.g004
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For TBEV-infected sera, 4/10 samples were detected as negative, 3/10 as equivocal and 3/10 as
positive (Fig 5). Comparison with the values obtained using DENV Ewt showed a similar
cross-reactivity. In contrast, when using the DENV 1–4 Equad mixture high signals were
obtained only with the three DENV-infected sera (mean values of 1.5, 1.6 and 1.7, respectively)
and cross-reactivity was strongly reduced in all samples fromWNV- and TBEV-infections
(mean values all>0,3, Fig 5).
Subsequently, the proteins were used to measure IgM antibodies in human sera. 300 ng of
DENV 1–4 Equadmix were found to be optimal for IgM detection (S3 Table), which was then com-
pared to 300 ng of DENV-2 Ewt in binding of IgM-positive DENV andWNV sera. Generally, the
cross-reactivity of heterologous flavivirus IgM antibodies was lower than for IgG, as demonstrated
by less binding to the Ewt protein (Fig 6A). By using the DENV 1–4 Equadmixture the mean value
of signals for DENV sera was enhanced as compared for DENV-2 Ewt. On the other hand,WNV
cross-reactivity was significantly reduced in comparison to DENV-2 Ewt (Fig 6B and S2 Table).
Discussion
A challenge for current serological dengue diagnosis is the high degree of cross-reactivity
between antibodies produced during infections with related flaviviruses [27–29], leading to
Fig 5. Comparison of different antigens for the detection of DENV IgG. Sera positive for IgG against DENV, WNV, TBEV or negative control sera were
analyzed with the Panbio Indirect IgG ELISA (black), the DENV-2 Ewt protein (light gray, lined) or the DENV1-4 Equad mix (dark grey, lined). The absolute
absorbance is indicated. Cut-Off values for the Panbio test were obtained by calculation of the internal standard of the manufacturer; these are indicated at
the right and only refer to this test (horizontal bars: DENV-positive results with an OD-value higher than 1.1*cut-off, equivocal results having an OD-value
between 1.1*cut-off and 0.9*cut-off, negative results with an OD-value lower than 0.9*cut-off).
doi:10.1371/journal.pntd.0004218.g005
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false positive results in currently available serological test systems [11,12]. Especially in areas
with different co-circulating flaviviruses, this is of concern [1,14]. Here, we present insect-cell
derived recombinant DENV E proteins bearing mutations in the conserved FL domain to
enhance the specificity of serological DENV diagnosis. When using the wild type E protein
from serotype 2 (which is the basis for several available test systems) we found all the DENV-
positive sera displayed high signals (Fig 4A). However, the cross-reactivity problem was also
confirmed, as the signals obtained with many WNV- and TBEV positive samples were in the
range of DENV-signals, although the mean intensities were lower (Figs 3E and 4A). As a conse-
quence, several sera would be misdiagnosed as false-positive, which was indeed observed when
a commercial assay was used (Fig 5).
It has been shown before that a large proportion of antibodies to DENV-infections are pro-
duced against the FL domain [17,18,22]. Accordingly, two out of three dengue sera showed a
clearly decreased signal when the FL-mutant version of the E-protein from DENV-2 was used
(Fig 3B and 3E). However, in the larger serum panel, the signals obtained with the DENV-sera
remained detectable, but most of the binding of the heterologous flavivirus-antibodies was
eliminated (Figs 3B and 4B). This result confirms previous studies performed with WNV and
JEV, using VLP-based systems with single- or double mutations in the FL domain [20,21] and
underlines the role of the conserved FL domain in cross-reactivity between flavivirus-antibod-
ies. It also demonstrates that the four mutations of the Equad proteins fromWNV [24] can be
used to eliminate cross-reactive epitopes in DENV E proteins. When the mixture of all four
serotype-specific mutant proteins was used, the values of many DENV-positive serum samples
increased as compared to using DENV-2 Equad only, although only half the amount of total
Fig 6. IgM-ELISA on 300 ng of DENV-2 Ewt (A) and DENV 1–4 Equadmixture (B) with different DENV, WNV and negative (NEG) sera (n = number of
individuals). Bottom and top of the boxes are the first and third quartiles. The median signal is depicted as a line inside the box. Whiskers represent the 9th
and the 91st percentile. Measurements were performed in duplicates in at least two independent experiments.
doi:10.1371/journal.pntd.0004218.g006
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protein was used (Fig 4C). This increase in sensitivity might result from serum samples that
were from non-serotype 2 infections and now bound to their corresponding E-protein, such as
the three outliers in Fig 4B. However, in the absence of knowledge of the infecting serotype,
this interpretation remains speculative. Data on the infecting serotypes were available only for
a limited subset of the DENV-positive sera in this study. In addition to an increase in sensitiv-
ity, the cross-reactivity of TBEV andWNV sera was further reduced with the serotype mixture
and lower amount of antigen. Under the conditions used, all DENV-infected sera of the panel
led to high absorbance values with the DENV 1–4 mix. Nevertheless, to avoid single outliers,
the exact relative contribution and amount of each serotype mutant protein in the mixture
might still be optimized. The titration curves (Fig 3) suggest that a doubling of the amount of
the individual mutant antigens does still not lead to an increase in cross-reactivity.
Using the DENV 1–4 mix for IgM detection resulted in a higher mean value of positive sam-
ples as compared to the wildtype antigen (Fig 6). At the same time, the cross-reactivity with
WNV-positive sera was decreased. Due to the generally observed higher specificity of IgM-
antibodies [12], this improvement in specificity was less pronounced as for IgG-detection (Fig
6). Nevertheless, our data support the idea that recombinant E proteins bearing four point
mutations are suitable antigens for the specific serological diagnosis of dengue. This is also sup-
ported by testing samples from a recent external quality assessment on serological dengue diag-
nosis [12], where the vast majority of participating laboratories (using various ELISA systems)
detected a cross-reactive WNV serum as false positive. The serotype mixture used here was
able to detect the samples with 100% accuracy (results are included in Fig 4), including diluted
samples for sensitivity determination. In addition, the direct comparison of the DENV-1-4
mixture antigen with a commercially available test clearly showed the increased specificity of
the mutant antigens (Fig 5). Although no cut-offs were yet defined for the DENV1-4 Equad, it
is clear from Figs 4 and 5 that cross-reactive sera cause absorbance values more similar to flavi-
virus-negative than to DENV-positive samples.
We recently have performed a study using a bacterially expressed Equad mutant for WNV
[24]. These data also showed a reduction in cross-reactivity. However, especially some DENV-
positive samples with a high antibody titer still bound the mutant protein to some extent.
Therefore, the ratio between signals obtained with the wildtype and mutant protein was calcu-
lated for each serum enabling correct diagnosis. In contrast, in the present study the mutant
proteins alone were sufficient to exclude cross-reactivity, which might reflect higher sensitivity
of the insect-cell derived antigen or specific differences between the antibody responses to
WNV and DENV.
In summary, a system for the sensitive and specific serological diagnosis of DENV-infec-
tions is presented, which consists of recombinant E-proteins from the four major serotypes,
with mutations in the FL and an adjacent loop domain. The binding of cross-reactive antibod-
ies from heterologous flavivirus-infections is strongly decreased. These antigens might form a
valuable basis for improved antibody tests, especially in areas where co-circulation of different
flaviviruses is observed.
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